Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Neurophth Closes $95 Million Series C+ Round for Gene Therapy Ophthalmology Therapies

publication date: Aug 11, 2023

Neurophth Therapeutics, a Wuhan-San Diego company, closed a $95 million Series C+ financing to advance its portfolio of gene therapy ophthalmology therapies and expand its R&D operations. In early 2023, Neurophth's lead therapy, NR082 (rAAV2-ND4), finished enrolling patients in a China Phase III trial as a therapy for Leber's hereditary optic neuropathy (LHON), a rare disease. The company has also enrolled the first patient for Phase I/II clinical trials of NR082 in the US. The round was co-led by Yangtze River-CMB International Industry Fund, Wuhan Optical Valley Financial Holding Group and other companies. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital